Steven Cohen Astria Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding ATXS
# of Institutions
115Shares Held
51.9MCall Options Held
48KPut Options Held
9.3K-
Perceptive Advisors LLC New York, NY6.49MShares$45.4 Million1.91% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$35.7 Million0.73% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$29.3 Million2.22% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$24.9 Million6.29% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$24.6 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $106M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...